Skip to content

Safety and Efficacy of I 0401 in the Treatment of Tibial Plateau Fractures Requiring Grafting

A Phase 2 Randomized, Controlled, Open-label (Dose-blinded), Multi-center, Dose-finding Study of the Safety and Efficacy of I-0401 in the Treatment of Patients With Fractures of the Tibial Plateau Requiring Grafting.

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00409799
Enrollment
208
Registered
2006-12-11
Start date
2006-11-30
Completion date
2011-09-30
Last updated
2012-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tibia Plateau Fractures

Keywords

Bone graft substitute, Promotion of bone healing

Brief summary

For certain tibial plateau fractures the bone is compressed due to the force acting on the tibia during the accident. The void provoked by the compression of the bone is filled with an appropriate filling material and the fracture is fixated. I 0401 is a new bone graft substitute that has shown capacities to promote bone-healing. This study will test the safety and efficacy of I 0401 in the treatment of patients with tibial plateau fractures requiring grafting.

Interventions

DRUGI-0401 (a new bone graft substitute)

1 time application

Sponsors

Kuros Biosurgery AG
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Radiological evidence of a tibial plateau fracture requiring grafting * Females of child-bearing potential must be willing to undergo a pregnancy test (urine) prior to treatment start (at screening).

Exclusion criteria

* Concomitant ipsilateral fractures of the limb other than the fracture of the tibial plateau. * Active or past history of malignant tumor. * Evidence of systemic or localized infection at time of surgery. * Pregnant or lactating females.

Design outcomes

Primary

MeasureTime frame
Radiographic ImagesAll Follow-Up Visits

Secondary

MeasureTime frame
Clinical assessments of the fracture siteAll Follow-Up Visits
Blood parametersAll Follow-Up Visits
Vital signsAt several Follow-Up visits
Questionnaires of LifeAll Follow-Up Visits
Pharmacoeconomic evaluationAll Follow-Up Visits

Countries

Australia, France, Germany, Hungary, Italy, Poland, Spain, Switzerland, United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026